-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
MK-2048
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/869901-69-9.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 869901-69-9 |
| Description | MK-2048 is a second generation integrase inhibitor (IC50=2.6 nM). It can inhibits the HIV enzyme integrase 4 times longer than raltegravir. |
Product Information
| Synonyms | MK2048; MK 2048; MK-2048 |
| IUPAC Name | (13S)-5-[(3-chloro-4-fluorophenyl)methyl]-11-ethyl-8-hydroxy-N,13-dimethyl-6,10-dioxo-1,4,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2(7),3,8-triene-3-carboxamide |
| Molecular Weight | 441.46 |
| Molecular Formula | C22H24FN5O4 |
| Canonical SMILES | CCN1CC(N2C3=C(C(=C2C1=O)O)C(=O)N(N=C3C(=O)NC)CC4=CC(=C(C=C4)F)Cl)C |
| InChI | InChI=1S/C21H21ClFN5O4/c1-4-26-8-10(2)28-16-14(18(29)17(28)21(26)32)20(31)27(25-15(16)19(30)24-3)9-11-5-6-13(23)12(22)7-11/h5-7,10,29H,4,8-9H2,1-3H3,(H,24,30)/t10-/m0/s1 |
| InChIKey | JSRREMIKIHJGAA-JTQLQIEISA-N |
| Purity | >98% |
| Density | 1.6±0.1 g/cm3 |
| Solubility | DMSO: 9 mg/mL (19.48 mM) Water: Insoluble Ethanol: Insoluble |
| Appearance | Solid powder |
| Storage | Powder: 3 years -20°C In solvent: 2 years -80°C |
| Complexity | 828 |
| Exact Mass | 461.1266100 |
| Index Of Refraction | 1.698 |
| PSA | 109.46000 |
| Target | HCV |
| XLogP3-AA | 2.3 |